此服务在您所在的地区不可用。

6 4 G LTD

英国

成立于

2015 (11 年)

成立

最后在线: 最近无活动

访问网站

暂无 TrustScore分数不足，无法显示趋势。

成为首个为该公司评分和评论的用户。

综合得分

牌照

--/40

--/60

0 条评价

由 TrustFinance 提供

暂无 TrustScore分数不足，无法显示趋势。

成为首个为该公司评分和评论的用户。

受监管的

IUX

(2,283 评论)

Mauritius

2016

(10 年)

安全信息 :

FSCA

FSC

ASIC

安全信息

警告

该公司目前未经证实.

请注意潜在风险！

牌照

甲級牌照

由全球知名监管机构颁发，这些许可证通过严格的合规性、资金隔离、保险和定期审计，确保最高程度的交易者保护。争议解决和遵守 AML/CTF 标准进一步提高了安全性。

B 級牌照

由受尊敬的区域监管机构授予，这些许可证提供强大的安全措施，例如资金隔离、财务报告和补偿计划。虽然没有等级 1 那么严格，但它们提供可靠的区域保护。

C 級牌照

由新兴市场的监管机构颁发，这些许可证提供基本保护，例如最低资本要求和 AML 政策。监管较不严格，因此交易者应谨慎行事并验证安全措施。

D 級牌照

来自监管最少的司法管辖区，这些许可证通常缺乏关键保护，例如资金隔离和保险。虽然它们对运营弹性很有吸引力，但它们对交易者构成较高的风险。

公司資料

了解 6 4 G LTD

公司資料

了解 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

行业

外汇零售经纪人主要
金融其他服务

软件

没有可用的数据

看起来这个部分是空的。请尽快回来获取更新！

联络

社交

公司尚未更新其信息。

6 4 G LTD 评论

总计 0

排序依据

过滤器

公司資料

了解 6 4 G LTD

公司資料

了解 6 4 G LTD

6 4 G LTD, operating under the brand name 64FX, is an online trading provider incorporated in St. Vincent & the Grenadines. The company's mission is to offer a transparent and high-quality trading environment for both retail and institutional clients. It provides access to global financial markets, including Forex, indices, commodities, and shares, utilizing the popular MetaTrader 5 trading platform and offering various account types to suit different trading needs.

行业

外汇零售经纪人主要
金融其他服务

软件

没有可用的数据

看起来这个部分是空的。请尽快回来获取更新！

联络

社交

公司尚未更新其信息。

新聞

TrustFinance 情報機構

研究日期: 5月 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

由TrustFinance AI分析提供

新聞

TrustFinance 情報機構

研究日期: 5月 14, 2026

The website provides comprehensive resources and tools related to personal finance, including credit cards, banking, loans, insurance, investing, small business, and taxes. Users can compare various financial products, access calculators, and read guides to help make informed financial decisions. The site emphasizes independent and objective information while also featuring partner compensation disclosures.

The article discusses GeneAgent, an AI tool designed for gene-set analysis that utilizes large language models (LLMs) to autonomously verify its outputs through interactions with biological databases. It aims to reduce inaccuracies, referred to as 'hallucinations', commonly associated with LLMs. GeneAgent has been evaluated against existing models, showing superior accuracy in generating functional descriptions for gene sets. The study highlights the importance of self-verification in enhancing the reliability of gene function annotations, showcasing GeneAgent's ability to produce informative insights from gene sets derived from various sources, including mouse melanoma cell lines.

The article presents the development and validation of an autonomous artificial intelligence (AI) agent designed to assist in clinical decision-making for oncology. This AI agent integrates multimodal data and utilizes advanced tools, including GPT-4, to support personalized treatment strategies. It was evaluated using 20 realistic patient cases, achieving high accuracy in clinical conclusions and effectively citing relevant oncology guidelines. The study illustrates how combining language models with precision oncology tools can enhance decision-making accuracy, paving the way for AI-driven personalized oncology support systems.

Medicare Supplement Plan G is a high-coverage insurance plan for new Medicare members, covering most out-of-pocket costs not included in Original Medicare, such as copayments and deductibles. It offers comprehensive coverage, including excess charge coverage, but comes with higher premiums. The plan is standardized, meaning all providers offer the same benefits regardless of price. While it does not cover the Part B deductible, it is often considered a valuable option for those willing to pay more for extensive benefits. The best time to enroll is during the six-month open enrollment period starting at age 65 and enrolled in Medicare Part B.

The study investigates zilebesiran, an RNA interference therapeutic agent targeting angiotensinogen, for managing hypertension. In a phase 1 trial, 107 patients received varying doses of zilebesiran or placebo. Results showed significant dose-dependent reductions in serum angiotensinogen levels and sustained decreases in systolic and diastolic blood pressure for up to 24 weeks. Mild injection-site reactions were noted, with no serious adverse events related to hypotension or renal function. The findings support further evaluation of zilebesiran as a potential treatment for hypertension.

由TrustFinance AI分析提供

6 4 G LTD

IUX

公司資料

公司資料

评论

6 4 G LTD 评论

评论

总计 0

6 4 G LTD

IUX

公司資料

公司資料

睇6 4 G LTD嘅用戶仲睇…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

新聞

TrustFinance 情報機構

评论

6 4 G LTD 评论

评论

总计 0

睇6 4 G LTD嘅用戶仲睇…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

新聞

TrustFinance 情報機構